Citations

Clear

9383 citation(s) found for "Thomas, PS".

KCNQ1 suppression-replacement gene therapy in transgenic rabbits with type 1 long QT syndrome
Bains, Sahej , Giammarino, Lucilla , Nimani, Saranda , Alerni, Nicolò , Tester, David J. , Kim, C.S. John, Christoforou, Nicolas , Louradour, Julien , Beslac, Olgica, Barbieri, Miriam , Matas, Lluis , Hof, Thomas , López, Rubén , Perez‐Feliz, Stefanie , Casalta, L.G. Garcia, Jurgensen, Jacqulyn, Bego, Mariana G. , Keyes, Lisa R., Owens, Jane , Pinkstaff, Jason, Koren, Gideon , Zehender, Manfred, Brunner, Michael, Casoni, Daniela , Brooks, Gabriel , Ackerman, Michael J. , Odening, Katja E. , Brunner, Michael , Praz, Fabien , Haeberlin, Andreas , Ackerman, Michael J , Odening, Katja E , Bains, Sahej , Horváth, András , Parodi, Chiara, Barry, Michael A. , Praz, Fabien

Mayo Clinic

European Heart Journal | August 8, 2024 | Volume: 45 | Issue: 36 | Pages: 3751-3763

10.1093/eurheartj/ehae476 | PMID 39115049 Get It

Abstract Background and Aims Type 1 long QT syndrome (LQT1) is caused by pathogenic variants in the KCNQ1-encoded Kv7.1 potassium channels, which pathologically prolong ventricular action potential duration (APD). Herein, the pathologic phenotype in transgenic LQT1 rabbits is rescued using a novel KCNQ1 suppression-replacement (SupRep) gene therapy. Methods KCNQ1-SupRep gene therapy was developed by combining into a single construct a KCNQ1 shRNA (suppression) and an shRNA-immune KCNQ1 cDNA (replacement), packaged into adeno-associated virus serotype 9, and delivered in vivo via an intra-aortic root injection (1E10 vg/kg). To ascertain the efficacy of SupRep, 12-lead electrocardiograms were assessed in adult LQT1 and wild-type (WT) rabbits and patch-clamp experiments were performed on isolated ventricular cardiomyocytes. Results KCNQ1-SupRep treatment of LQT1 rabbits resulted in significant shortening of the pathologically prolonged QT index (QTi) towards WT levels. Ventricular cardiomyocytes isolated from treated LQT1 rabbits demonstrated pronounced shortening of APD compared to LQT1 controls, leading to levels similar to WT (LQT1-UT vs. LQT1-SupRep, P < .0001, LQT1-SupRep vs. WT, P = ns). Under β-adrenergic stimulation with isoproterenol, SupRep-treated rabbits demonstrated a WT-like physiological QTi and APD90 behaviour. Conclusions This study provides the first animal-model, proof-of-concept gene therapy for correction of LQT1. In LQT1 rabbits, treatment with KCNQ1-SupRep gene therapy normalized the clinical QTi and cellular APD90 to near WT levels both at baseline and after isoproterenol. If similar QT/APD correction can be achieved with intravenous administration of KCNQ1-SupRep gene therapy in LQT1 rabbits, these encouraging data should compel continued development of this gene therapy for patients with LQT1.
Proposals for revised International Working Group–European LeukemiaNet criteria for anemia response in myelofibrosis
Tefferi, Ayalew , Barosi, Giovanni , Hernández‐Boluda, Juan Carlos , Bose, Prithviraj , Döhner, Konstanze , Gangat, Naseema , Garcia, Jacqueline S. , Gisslinger, Heinz , Gupta, Vikas , Harrison, Claire , Loscocco, Giuseppe Gaetano , Mora, Barbara , Odenike, Olatoyosi, Pardanani, Animesh , Patel, Anand , Pemmaraju, Naveen , Rampal, Raajit K. , Sirhan, Shireen , Vachhani, Pankit , Vannucchi, Alessandro M., Barbui, Tiziano , Hernández-Boluda, Juan Carlos , Bose, Prithviraj , Gangat, Naseema , Garcia, Jacqueline S , Gupta, Vikas , Hexner, Elizabeth , Hobbs, Gabriela S , Koschmieder, Steffen , Kuykendall, Andrew , Loscocco, Giuseppe Gaetano , Mascarenhas, John , Masarova, Lucia , Mesa, Ruben , Oh, Stephen T , Patel, Anand , Pemmaraju, Naveen , Rambaldi, Alessandro , Szuber, Natasha , Vachhani, Pankit , Barbui, Tiziano , Passamonti, Francesco , Ellis, Martin H. , Gotlib, Jason , Guglielmelli, Paola , Hexner, Elizabeth O. , Hobbs, Gabriela , Kiladjian, Jean‐Jacques , Koschmieder, Steffen , Kröger, Nicolaus , Mascarenhas, John , Masárová, Lucia , Mesa, Ruben A. , Odenike, Olatoyosi , Oh, Stephen T. , Rambaldi, Alessandro , Szuber, Natasha , Talpaz, Moshe

Mayo Clinic

Blood | August 8, 2024 | Volume: 144 | Issue: 17 | Pages: 1813-1820

10.1182/blood.2024025802 | PMID 39116296 Get It

Abstract With emerging new drugs in myelofibrosis (MF), a robust and harmonized framework for defining the severity of anemia and response to treatment will enhance clinical investigation and facilitate interstudy comparisons. Accordingly, the lead authors on the 2013 edition of the International Working Group–European LeukemiaNet (IWG-ELN) response criteria in MF were summoned to revise their document with the intent to (1) account for gender-specific differences in determining hemoglobin levels for eligibility criteria; (2) revise the definition of transfusion-dependent anemia (TDA) based on current restrictive transfusion practices; and (3) provide a structurally simple and easy to apply response criteria that are sensitive enough to detect efficacy signals (minor response) and also account for major responses. The initial draft of the 2024 IWG-ELN proposed criteria was subsequently circulated around a wider group of international experts and their feedback incorporated. The proposed articles include new definitions for TDA (≥3 units in the 12 weeks before study enrollment) and hemoglobin thresholds for eligibility criteria (<10 g/dL for women and <11 g/dL for men). The revised document also provides separate (TDA vs non-TDA) and graded (major vs minor response) response criteria while preserving the requirement for a 12-week period of screening and observation on treatment.
Design and validation of the ADNI MR protocol
Arani, Arvin , Borowski, Bret, Felmlee, John, Thomas, David L. , Gunter, Jeffrey L. , Stables, Lara, Jung, Youngkyoo , Tosun, Duygu , Weiner, Michael W. , Jack, Clifford R. , Initiative, for the Alzheimer's Disease Neuroimaging, Tosun, Duygu , Jack, Clifford R , Arani, Arvin , Tosun, Duygu , Reid, Robert I. , Buckner, Randy L. , Initiative, for the Alzheimer's Disease Neuroimaging

Mayo Clinic

Alzheimer's & Dementia | August 8, 2024 | Volume: 20 | Issue: 9 | Pages: 6615-6621

10.1002/alz.14162 | PMID 39115941 Get It

AbstractPhase four of the Alzheimer's Disease Neuroimaging Initiative (ADNI4) magnetic resonance imaging (MRI) protocols aim to maintain longitudinal consistency across two decades of data acquisition, while adopting new technologies. Here we describe and justify the study's design and targeted biomarkers. The ADNI4 MRI protocol includes nine MRI sequences. Some sequences require the latest hardware and software system upgrades and are continuously rolled out as they become available at each site. The main sequence additions/changes in ADNI4 are: (1) compressed sensing (CS) T1‐weighting, (2) pseudo‐continuous arterial spin labeling (ASL) on all three vendors (GE, Siemens, Philips), (3) multiple‐post‐labeling‐delay ASL, (4) 1 mm3 isotropic 3D fluid‐attenuated inversion recovery, and (5) CS 3D T2‐weighted. ADNI4 aims to help the neuroimaging community extract valuable imaging biomarkers and provide a database to test the impact of advanced imaging strategies on diagnostic accuracy and disease sensitivity among individuals lying on the cognitively normal to impaired spectrum.Highlights A summary of MRI protocols for phase four of the Alzheimer's Disease Neuroimaging Initiative (ADNI 4). The design and justification for the ADNI 4 MRI protocols. Compressed sensing and multi‐band advances have been applied to improve scan time. ADNI4 protocols aim to streamline safety screening and therapy monitoring. The ADNI4 database will be a valuable test bed for academic research.
Perceptions, prevalence, and patterns of cannabis use among cancer patients treated at 12 NCI-Designated Cancer Centers
Ellison, Gary L. , Helzlsouer, Kathy J. , Rosenfield, Sonia , Cullen, Jennifer, Doran, Neal , Ebbert, Jon O. , Egan, Kathleen M. , McDaniels‐Davidson, Corinne , Hernandez-Ortega, Nicholas, Salz, Talya , Vidot, Denise C , Zylla, Dylan M. , Rosenfield, Sonia M , Doran, Neal , McDaniels-Davidson, Corinne , Kim, Yun , Ashare, Rebecca L. , Blaes, Anne , Heffner, Jaimee L. , Lee, Richard T. , McClure, Erin A. , Meghani, Salimah H. , Newcomb, Polly A. , Nugent, Shannon M. , Worster, Brooke K. , Zylla, Dylan

Mayo Clinic

JNCI Monographs | August 7, 2024 | Volume: 2024 | Issue: 66 | Pages: 202-217

10.1093/jncimonographs/lgae029 | PMID 39108244 Get It

Abstract Background The legal climate for cannabis use has dramatically changed with an increasing number of states passing legislation legalizing access for medical and recreational use. Among cancer patients, cannabis is often used to ameliorate adverse effects of cancer treatment. Data are limited on the extent and type of use among cancer patients during treatment and the perceived benefits and harms. This multicenter survey was conducted to assess the use of cannabis among cancer patients residing in states with varied legal access to cannabis. Methods A total of 12 NCI-Designated Cancer Centers, across states with varied cannabis-access legal status, conducted surveys with a core questionnaire to assess cannabis use among recently diagnosed cancer patients. Data were collected between September 2021 and August 2023 and pooled across 12 cancer centers. Frequencies and 95% confidence intervals for core survey measures were calculated, and weighted estimates are presented for the 10 sites that drew probability samples. Results Overall reported cannabis use since cancer diagnosis among survey respondents was 32.9% (weighted), which varied slightly by state legalization status. The most common perceived benefits of use were for pain, sleep, stress and anxiety, and treatment side effects. Reported perceived risks were less common and included inability to drive, difficulty concentrating, lung damage, addiction, and impact on employment. A majority reported feeling comfortable speaking to health-care providers though, overall, only 21.5% reported having done so. Among those who used cannabis since diagnosis, the most common modes were eating in food, smoking, and pills or tinctures, and the most common reasons were for sleep disturbance, followed by pain and stress and anxiety with 60%-68% reporting improved symptoms with use. Conclusion This geographically diverse survey demonstrates that patients use cannabis regardless of its legal status. Addressing knowledge gaps concerning benefits and harms of cannabis use during cancer treatment is critical to enhance patient-provider communication.
Recommendations of the Blue Ribbon Committee II for the Optimization of Surgical Education and Training in the United States
Johnson, Wali R. , Mainali, Bigyan B. , Chen, Xiaodong, Martin, Rebecca , Dawson-Amoah, Kwesi G, Doyle, Kathleen M., Ellis, Danielle , Fazzone, Brian , Hoefer, Lea , Riner, Andrea N. , Shin, Thomas , Yelorda, Kirbi , Kearse, LaDonna , Chen, Xiaodong, Alobuia, Wilson Mawutor , Anderson, Erik M., Martin, Rebecca, Caldwell, Katharine E. , Dawson-Amoah, Kwesi G., Ghio, Michael , Godfrey, Caroline M. , Gomes, Camilla , Niehaus, Hannah, Phelps, Hannah M. , Sharon, Cimarron E. , Coleman, Julia R.

Mayo Clinic

Annals of Surgery | August 7, 2024 | Volume: 281 | Issue: 1 | Pages: 40-45

10.1097/sla.0000000000006483 | PMID 39109446 Get It

Objective: This study aims to appraise recommendations from an expert panel of surgical educators on optimizing surgical education and training in the setting of contemporary challenges. Background: The Blue Ribbon Committee (BRC II), a group of surgical educators, was convened to make recommendations to optimize surgical training, considering the current changes in the landscape of surgical education. Surgical trainees were recruited to assess their impressions of the recommendations. Methods: A mixed-methods study design was employed, with a survey, followed by focus group interviews. Participating residents and fellows were recruited through a purposeful sampling approach. Descriptive statistics were applied to analyze the survey data, and a thematic data analysis on interview transcripts was employed. Results: The majority of trainee respondents (n=16) thought that all of the subcommittee recommendations should be included in the final BRC II recommendations and paper. According to the interviews, overall, the feedback from the trainees was positive, with particular excitement around work-life integration, education support and faculty development, and funding pitfalls. Some themes about concerns included a lack of clarity about the recommendations, concern about some recommendations being in conflict with one another, and a disconnect between the initial BRC II survey and the subsequent recommendations. Conclusions: The residents gathered for this focus group were encouraged by the thought, effort, and intention that gathered the surgical leaders across the country to make the recommendations. While the trainees wanted clarity on some areas, the overall opinion was in agreement with the recommendations.
Characteristics of rehabilitation protocols following operative treatment of terrible triad elbow injuries and the influence of early motion: A systematic review and meta-analysis
Larwa, Joseph , Buchanan, Timothy R. , Janke, Rachel L. , Burns, Madison Q. , Wright, Logan , Hao, Kévin A. , Cueto, Robert J. , Hones, Keegan M. , Aibinder, William R. , Wright, Thomas W. , Schoch, Bradley S , King, Joseph J , Hao, Kevin A , Aibinder, William R , Hones, Keegan M , Wright, Logan, Schoch, Bradley S. , King, Joseph J.

Mayo Clinic

Shoulder & Elbow | August 6, 2024 | Volume: 17 | Issue: 6 | Pages: 831-843

10.1177/17585732241269807 | PMID 39552691 Get It

Background As no consensus exists on the optimal postoperative rehabilitation protocol in terrible triad injuries, we sought to characterize the reported protocols and relate them to postoperative range of motion (ROM) measures and Mayo Elbow Performance Score (MEPS). Methods A systematic review was performed by searching PubMed/MEDLINE, Embase, Web of Science, and Cochrane databases to identify articles on the operative treatment of terrible triad injuries reporting postoperative rehabilitation protocols were included. Included studies were descriptively summarized. Methodologic quality was assessed using the Methodological Index for Non-randomized Studies criteria. Meta-analysis compared postoperative ROM measures and the MEPS between patients initiating passive ROM exercises at ≤7 days vs. >7 days. Results Our review included 36 articles with 1123 elbows (66% male, mean age: 43 years, follow-up: 27 months). Of the studies reporting physical therapy protocols, it was most commonly initiated at 7 days postoperatively (6/36, 17%), passive ROM exercises at 7 days (3/25, 12%), and active ROM at 21 days (4/26, 15%). On meta-analysis, early passive ROM initiation was not associated with improved elbow ROM or MEPS. Discussion While rehabilitation protocols commonly advised passive ROM at one week post-operatively, meta-analysis did not support functional benefits of early passive ROM. Study design Systematic Review; Level of evidence, 4.
Simultaneous onset of chronic nonbacterial osteomyelitis in siblings
Patel, Jenny A. , Thomas, Kristen B. , Ristagno, Elizabeth H. , Basiaga, Matthew L.

Mayo Clinic

Modern Rheumatology Case Reports | August 3, 2024 | Volume: 9 | Issue: 1 | Pages: 20-26

10.1093/mrcr/rxae035 | PMID 39096523 Get It

ABSTRACT Chronic nonbacterial osteomyelitis (CNO) is an uncommon autoinflammatory disorder. Significant effort has recently been spent to better define and treat this disorder including development of consensus treatment protocols, validate disease activity tools, and refining classification criteria. However, the underlying immunopathogenesis of the disease remains elusive. In this report, we describe the simultaneous onset of CNO in siblings. A pathogenic gene mutation was not identified, and these sisters lacked a similar biomarker profile. This report highlights that if a genetic predisposition for CNO exists, it may be related to complex polygenic or multifactorial mechanisms of disease evolution.
Racial and ethnic disparities in the natural history of alcohol‐associated liver disease in the United States
Ayares, Gustavo , Díaz, Luis Antonio , Fuentes–López, Eduardo , Idalsoaga, Francisco , Cotter, Thomas G. , Dunn, Winston , Shah, Vijay H. , Kamath, Patrick S. , Lazarus, Jeffrey V. , Simonetto, Douglas A , Kamath, Patrick S , Lazarus, Jeffrey V , Bataller, Ramon A , Arrese, Marco , Wong, Robert J , Singal, Ashwani K , Arab, Juan P , Cotter, T G , Díaz, Luis A , Ayares, Gustavo , Dunn, Winston , Simonetto, Douglas A. , Arrese, Marco , Wong, Robert J. , Singal, Ashwani K. , Arab, Juan Pablo

Mayo Clinic

Liver International | August 3, 2024 | Volume: 44 | Issue: 10 | Pages: 2822-2833

10.1111/liv.16023 | PMID 39096099 Get It

Abstract Background Outcomes in alcohol‐associated liver disease (ALD) are influenced by several race and ethnic factors, yet its natural history across the continuum of patients in different stages of the disease is unknown. Methods We conducted a retrospective cohort study of U.S. adults from 2011 to 2018, using three nationally representative databases to examine potential disparities in relevant outcomes among racial and ethnic groups. Our analysis included logistic and linear regressions, along with competing risk analysis. Results Black individuals had the highest daily alcohol consumption (12.6 g/day) while Hispanic participants had the largest prevalence of heavy episodic drinking (33.5%). In a multivariable‐adjusted model, Hispanic and Asian participants were independently associated with a higher ALD prevalence compared to Non‐Hispanic White interviewees (OR: 1.4, 95% CI: 1.1–1.8 and OR: 1.5 95% CI:1.1–2.0, respectively), while Blacks participants had a lower ALD prevalence (OR: .7 95% CI: .6–.9), and a lower risk of mortality during hospitalization due to ALD (OR: .83 95% CI: .73–.94). Finally, a multivariate competing‐risk analysis showed that Hispanic ethnicity had a decreased probability of liver transplantation if waitlisted for ALD (SHR: .7, 95% CI: .6–.8) along with female Asian population (HR: .40, 95% CI: .26–.62). Conclusions After accounting for key social and biological health determinants, the Hispanic population showed an increased risk of ALD prevalence, even with lower alcohol consumption. Additionally, Hispanic and Asian female patients had reduced access to liver transplantation compared to other enlisted patients.
Leveraging Generative Artificial Intelligence Models in Patient Education on Inferior Vena Cava Filters
Singh, Som Pal, Jamal, Aleena, Qureshi, Farah, Zaidi, Rohma , Qureshi, Fawad , Qureshi, Fawad , Singh, Som P.

Mayo Clinic

Clinics and Practice | August 1, 2024 | Volume: 14 | Issue: 4 | Pages: 1507-1514

10.3390/clinpract14040121 | PMID 39194925 Get It

Background: Inferior Vena Cava (IVC) filters have become an advantageous treatment modality for patients with venous thromboembolism. As the use of these filters continues to grow, it is imperative for providers to appropriately educate patients in a comprehensive yet understandable manner. Likewise, generative artificial intelligence models are a growing tool in patient education, but there is little understanding of the readability of these tools on IVC filters. Methods: This study aimed to determine the Flesch Reading Ease (FRE), Flesch–Kincaid, and Gunning Fog readability of IVC Filter patient educational materials generated by these artificial intelligence models. Results: The ChatGPT cohort had the highest mean Gunning Fog score at 17.76 ± 1.62 and the lowest at 11.58 ± 1.55 among the Copilot cohort. The difference between groups for Flesch Reading Ease scores (p = 8.70408 × 10−8) was found to be statistically significant albeit with priori power found to be low at 0.392. Conclusions: The results of this study indicate that the answers generated by the Microsoft Copilot cohort offers a greater degree of readability compared to ChatGPT cohort regarding IVC filters. Nevertheless, the mean Flesch–Kincaid readability for both cohorts does not meet the recommended U.S. grade reading levels.
Recurrence of Non–Small Cell Lung Cancer With Visceral Pleural Invasion
Wang, Xiaofei , Damman, Bryce , Wigle, Dennis A. , Port, Jeffrey L., Ashrafi, Ahmad S., Liberman, Moïshe , Landreneau, Rodney J., Yasufuku, Kazuhiro, Yang, Stephen C. , Mitchell, John D. , Keenan, Robert J. , Miller, Daniel P. , Kozono, David , Mentlick, Jennifer, Vokes, Everett E., Stinchcombe, Thomas E. , Wigle, Dennis, Kozono, David E , Altorki, Nasser Khaled , Jones, David R. , Conti, Massimo , BAUER, THOMAS L , Miller, Daniel, Vokes, Everett E.

Mayo Clinic

JAMA Oncology | August 1, 2024 | Volume: 10 | Issue: 9 | Pages: 1179

10.1001/jamaoncol.2024.2491 | PMID 39088196 Get It

Importance The randomized clinical trial Cancer and Leukemia Group B (CALGB) 140503 showed that for patients with clinically staged T1N0 non–small cell lung cancer (NSCLC; ≤2 cm), sublobar resections were associated with similar oncological outcomes to those after lobar resection. The association of the extent of parenchymal resection with recurrence and survival in patients with tumors pathologically upstaged to T2 based on visceral pleural invasion (VPI) is controversial. Objective To determine survival and recurrence rates in patients with small peripheral pT2 NSCLC (≤2 cm) that was treated by either lobar or sublobar resection in CALGB 140503. Design, Participants, and Setting CALGB 140503, a randomized multicenter noninferiority trial, included 697 patients with small peripheral NSCLC that was clinically staged as T1N0. Enrollment was from June 2007 through March 2017 at 83 participating institutions, and after a median follow-up of 7 years, the primary outcome of disease-free survival after sublobar resection was noninferior to that after lobar resection. Intervention Lobar or sublobar resection. Main Outcomes and Measures Survival end points were estimated by the Kaplan-Meier estimator. Hazard ratios and 95% CIs were estimated using stratified Cox proportional hazard models. Results Of 679 participants, 390 (57.4%) were female, and the median (range) age was 67.8 (37.8-89.7) years. Among 697 patients randomized, 566 (81.2%) had pT1 tumors (no VPI) and 113 (16.2%) had pT2 tumors (VPI). Five-year disease-free survival was 65.9% (95% CI, 61.9%-70.2%) in patients with pT1 compared with 53.3% (95% CI, 44.3%-64.1%) in patients with pT2 tumors (stratified log-rank: P = .02). Disease recurrence developed in 27.6% of patients with pT1 (locoregional only: 60 [10.8%]; distant only: 81 [14.6%]) and 41.6% of those with pT2 (locoregional only: 17 [15.0%]; distant only: 27 [23.9%]). Five-year recurrence-free survival was 73.1% (95% CI, 69.2%-77.1%) for pT1 tumors and 58.2% (95% CI, 49.2%-68.8%) for pT2 tumors (stratified log-rank: P = .01). There were no intergroup differences in disease-free or recurrence-free survival based on the extent of parenchymal resection. Conclusions and Relevance The results of this secondary analysis suggest that compared with patients with tumors without VPI, patients who had tumors with VPI had worse disease-free and recurrence-free survival and a higher rate of local and distant disease recurrence. These high rates of recurrence were independent of the extent of parenchymal resection, and these data support the inclusion of these patients in adjuvant therapy trials. Trial Registration ClinicalTrials.gov Identifier: NCT0049933